Novel Imaging May Make Peritoneal Mesothelioma Surgery More Effective
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studied with women undergoing lumpectomy for breast cancer. It’s been lauded for its ability to identify hard-to-detect tumor cells beyond the margin of the specimen. This application involving cancers within the peritoneum was developed in the Cusack Laboratory. “This feasibility study is a critical first step in determining if the Lumicell System will be effective in improving quality of life for people with peritoneal metastasis,” Cusack said in a press release announcing the start of his study. “We will be…comparing the imaging results detected on the molecular level with the traditional microscopic evaluation, to improve surgical outcomes for patients with peritoneal surface malignancies.” Finding Hidden Tumor Cells Peritoneal mesothelioma is a diffuse and aggressive cancer that begins in the lining around the abdominal c...
Publication date: Available online 9 July 2020Source: Saudi Pharmaceutical JournalAuthor(s): Saranya Rameshbabu, Safia A. Messaoudi, Zeyad Ibrahim Alehaideb, Mohammed Syed Ali, Anuradha Venktraman, Hala Alajmi, Hamad Al-Eidi, Sabine Matou-Nasri
Publication date: Available online 8 July 2020Source: PhytomedicineAuthor(s): Safaa Yehia Eid, Mohammad Ahmad Althubiti, Michael Wink, Mahmoud Zaki El-Readi
PANCREATIC cancer is harder to treat in the later stages so it is important to act on the warning signs as soon as they appear. One warning can be seen in the colour of your urine.
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Sophie D. Fosså, Alv A. Dahl, Tor Å. Myklebust, Cecile E. Kiserud, Ragnhild Nome, Olbjørn H. Klepp, Marianne Brydøy, Hege S. Haugnes
Nanoparticle (NP)‐based drug‐delivery systems are frequently employed to improve the intravenous administration of chemotherapy; however, few reports explore their application as an intraperitoneal therapy. We developed a pH‐responsive expansile nanoparticle (eNP) specifically designed to leverage the intraperitoneal route of administration to treat intraperitoneal malignancies, such as mesothelioma, ovarian, and pancreatic carcinomatoses. This review describes the design, evaluation, and evolution of the eNP technology and, specifically, a Materials‐Based Targeting paradigm that is unique among the many active‐ ...
More News: Asbestosis | Breast Cancer | Breast Lumpectomy | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Environmental Health | Gastroenterology | Harvard | Hospitals | Laboratory Medicine | Lumpectomy | Mesothelioma | National Institutes of Health (NIH) | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study | Women